ABDXF (Abingdon Health) Current Deferred Revenue: $0.00 Mil (As of Dec. 2025)


ABDXF Abingdon Health PLC ABDXF
49 GF Score
Price $0.15
GF Value $0.21
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Abingdon Health Current Deferred Revenue?

Abingdon Health ABDXF 49 Current Deferred Revenue is $0.00 Mil as of Dec. 2025. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.21 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Abingdon Health's current deferred revenue for the quarter that ended in Dec. 2025 was $0.00 Mil.

Abingdon Health Current Deferred Revenue Related Terms

Abingdon Health Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Abingdon Health's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abingdon Health Current Deferred Revenue Chart

Abingdon Health Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Abingdon Health Semi-Annual Data
Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ABDXF
49GF Score
Abingdon Health PLC ABDXF
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.00 Mil mean?
Abingdon Health (ABDXF) has a Current Deferred Revenue of $0.00 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Abingdon Health and its competitors.
Is Abingdon Health's Current Deferred Revenue too high?
Abingdon Health's current Current Deferred Revenue is $0.00 Mil. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's Current Deferred Revenue compare to TMO and DHR?
Abingdon Health's Current Deferred Revenue of $0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Diagnostics & Research company?
A good Current Deferred Revenue depends on the Medical Diagnostics & Research industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Abingdon Health and its competitors. Abingdon Health's current Current Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.21, compared to a current price of $0.15 — trading 26.4% below its estimated fair value. The current Current Deferred Revenue is $0.00 Mil. Abingdon Health's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current Current Deferred Revenue is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abingdon Health (ABDXF) Overvalued in 2026?

Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued. The current stock price of $0.15 is trading 26.4% below its estimated GF Value™ of $0.21. GuruFocus considers Abingdon Health to be Modestly Undervalued.

Key valuation signals for ABDXF:

  • Current Deferred Revenue: $0.00 Mil
  • GF Value™: $0.21 vs. price of $0.15 (26.4% below fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abingdon Health Business Description

Other Exchanges ABDX:UK
Address York Biotech Campus, Sand Hutton, York, GBR, YO41 1LZ
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score

Get the complete analysis for ABDXF

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.21
GF Value